Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: Impact on plasma levels of HIV type 1 RNA and determinants of antibody response

被引:98
作者
Fuller, JD
Craven, DE
Steger, KA
Cox, N
Heeren, TC
Chernoff, D
机构
[1] Boston Univ, Med Ctr, Clin AIDS Program, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
[3] Boston Univ, Sch Publ Hlth, Epidemiol Sect, Boston, MA USA
[4] Boston Univ, Sch Publ Hlth, Hlth Serv Sect, Boston, MA USA
[5] Ctr Dis Control & Prevent, Atlanta, GA USA
[6] Chiron Corp, Emeryville, CA 94608 USA
关键词
D O I
10.1086/515170
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed the effect of influenza vaccination on plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and the impact of age, plasma HIV-1 RNA level, CD4 cell count, and anti-HIV therapy on immune response. Forty-nine adults (mean age, 38.7 years; mean CD4 cell count +/-SD, 190 +/- 169/mL; mean plasma HIV-1 RNA level +/- SD, 154,616 +/- 317,192 copies/mL) were immunized. Elevations of greater than or equal to 0.48 log in plasma HIV-1 RNA levels occurred in two (4%) of 49 subjects within 4 weeks of vaccination. A fourfold or greater increase in antibody titer occurred in 13 (45%) of 29 subjects, correlating directly with CD4 cell count (P =.002) and inversely with plasma HIV-1 RNA level (P =.034), By multivariate analysis, CD4 cell count was a stronger predictor of antibody response than was plasma HIV-1 RNA level. We conclude that increases in plasma HIV-1 RNA levels following influenza vaccination are rare and transient and that antibody response is impaired with CD4 cell counts of <100/mL and plasma HIV-1 RNA levels of > 100,000 copies/mL, Prospective trials are needed to evaluate the impact of highly active therapy on immune response after vaccination.
引用
收藏
页码:541 / 547
页数:7
相关论文
共 35 条
[1]   Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine [J].
Brichacek, B ;
Swindells, S ;
Janoff, EN ;
Pirruccello, S ;
Stevenson, M .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1191-1199
[2]  
CHAPMAN L, 1995, 2 NAT C HUMR ETR REL
[3]   SUSCEPTIBILITY TO INFLUENZA-A IN HIV-POSITIVE PATIENTS [J].
COHEN, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (02) :245-245
[4]  
CUTILLARGARCIA M, 1998, 5 C RETR OPP INF
[5]  
Donovan RM, 1997, AIDS, V11, P1054
[6]  
FINE AD, 1998, 47 ANN EP INT SERV C
[7]   Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients [J].
Fowke, KR ;
DAmico, R ;
Chernoff, DN ;
Pottage, JC ;
Benson, CA ;
Sha, BE ;
Kessler, HA ;
Landay, AL ;
Shearer, GM .
AIDS, 1997, 11 (08) :1013-1021
[8]   ZIDOVUDINE IMPROVES RESPONSE TO PNEUMOCOCCAL VACCINE AMONG PERSONS WITH AIDS AND AIDS-RELATED COMPLEX [J].
GLASER, JB ;
VOLPE, S ;
AGUIRRE, A ;
SIMPKINS, H ;
SCHIFFMAN, G .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (04) :761-764
[9]   Effect of influenza vaccination on human immunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study [J].
Glesby, MJ ;
Hoover, DR ;
Farzadegan, H ;
Margolick, JB ;
Saah, AJ .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1332-1336
[10]  
GREENBLATT R, 1997, 4 C RETR OPP INF